Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100758 | 0.83 | GABRR1 (0.35) | GABRR1GABBR2GABBR1 | |
| SCHEMBL9179936 | 0.78 | — | — | |
| Trifluoroacetic Acid SCHEMBL16394222 | 0.77 | GABRR1 (0.32) | GABRR1KDM4E | |
| SCHEMBL609003 | 0.76 | TSHR (0.35) | — | |
| SCHEMBL17791711 | 0.74 | MEN1 (0.31) | — | |
| SCHEMBL15968120 | 0.72 | CPB2 (0.37) | CPB2 | |
| SCHEMBL28712321 | 0.71 | LMNA (0.35) | — | |
| SCHEMBL15968437 | 0.71 | CPB2 (0.40) | CPB2 | |
| SCHEMBL8732964 | 0.68 | CHRM1 (0.35) | — | |
| SCHEMBL1345131 | 0.67 | GABRR1 (0.50) | GABRR1CPB2KDM4EGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | GABRR1 717/4885CPB2 672/4885KDM4E 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.